Alan Faulkner, MD
Ophthalmology · Honolulu, HINPI 1043312887
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Lensar, Inc. at 29.3% of the total. 2025 is the largest year on record at $32,727, 2.3 times the $13,937 reported in 2019. Among ophthalmology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $281.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$40K
- Bausch & Lomb Americas Inc.$31K
- Alcon$23K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$16K
- Amgen$6K
- Kala Pharmaceuticals, Inc.$6K
- plus $13K from 26 others
Across 2 payments — averaging $36,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$72K
What the payments were for
- Consulting fees$61,49346%
- Speaking & faculty fees$31,12623%
- Travel & lodging$2,0011%
- Food & beverage$40,28730%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 27 | $39,516 |
| Bausch & Lomb Americas Inc. | 80 | $31,138 |
| Alcon | 80 | $22,528 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 45 | $16,404 |
| Amgen(2 entities) | 34 | $6,072 |
| Kala Pharmaceuticals, Inc. | 21 | $5,845 |
| Omeros Corporation | 6 | $3,290 |
| Rxsight Inc | 20 | $1,824 |
| Eyevance Pharmaceuticals LLC | 7 | $1,526 |
| Glaukos Corporation | 9 | $1,422 |
| Eyepoint US, Inc. | 3 | $1,273 |
| Sun Pharmaceutical Industries Inc. | 29 | $803 |
| Novartis | 31 | $677 |
| Dompe US, Inc. | 16 | $509 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $439 |
| Shire North American Group Inc | 15 | $235 |
| Ivantis, Inc | 2 | $229 |
| Tarsus Pharmaceuticals, Inc. | 13 | $216 |
| Oyster Point Pharma, Inc. | 7 | $183 |
| Galderma Laboratories, L.p. | 3 | $163 |
| Harrow Eye, LLC | 4 | $148 |
| AbbVie(2 entities) | 5 | $107 |
| Sight Sciences, Inc. | 4 | $83 |
| Carl Zeiss Meditec, Inc. | 1 | $81 |
| Ziemer USA | 1 | $48 |
| Biotissue Holdings Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 2 | $27 |
| Kedrion Biopharma, Inc. | 1 | $25 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Welch Allyn | 1 | $19 |
| Staar Surgical Company | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$39,377
- MIEBO$23,381
- XIIDRA$17,404
- LOTEMAX SM$12,935
- ILUX$7,840
- WaveLight EX500 Excimer Laser$5,732
- TEPEZZA$5,651
- EYSUVIS$5,576
- Wavelight$4,155
- OMIDRIA$3,200
- Wavelight Refractive Suite$2,949
- Systane$2,450
- VYZULTA$1,565
- Flarex$1,450
- DEXYCU$1,200
- KXL System$1,050
- RXSIGHT CONTACT LENS$916
- RXSIGHT INJECTOR CARTRIDGE$916
- RXSIGHT INJECTOR HANDPIECE$916
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$916
How this compares
$134,926 in reported general payments places this provider in the 95th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lotemax SmLoteprednol Etabonate | 111 | $27,699 |
| BesivanceBesifloxacin Hcl | 114 | $25,450 |
| ProlensaBromfenac Sodium | 70 | $23,877 |
| Bromfenac Sodium | 37 | $7,863 |
| MoxifloxacinMoxifloxacin Hcl | 63 | $2,636 |
| Prednisolone Acetate | 49 | $1,363 |
| Ketorolac Tromethamine | 37 | $833 |
| Latanoprost | 23 | $391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa | $16,404 | $77,026295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
- Kenneth ChangHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.